Compare stocks

AB Science S.A. is a biotechnology company based in Paris, France, specializing in the research, development, and commercialization of protein kinase inhibitors. These are used in the treatment of cancers, chronic inflammatory diseases, and neurodegenerative disorders. Established in 2001, the company targets diseases with significant unmet medical needs through proprietary compounds, notably masitinib which is in various stages of clinical trials. AB Science operates primarily in Europe and has various products in its pipeline aimed at both human and veterinary medicine. Its strategic focus on niche therapeutic areas where there are few treatment options gives it a distinct position in the pharmaceutical industry.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.